Grasing Kenneth, He Shaunteng, Li Ning
Substance Abuse Research Laboratory, Kansas City Veterans Affairs Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, USA.
Pharmacol Res. 2005 Jan;51(1):69-78. doi: 10.1016/j.phrs.2004.07.004.
Selegiline is an irreversible inhibitor of monoamine oxidase (MAO) with psychostimulant and neuroprotective effects which can prevent decreases in dopamine efflux that follow opiate withdrawal. The present study evaluated effects of selegiline treatment on morphine-seeking behavior and morphine reinforcement in Wistar rats (n = 26). In additional animals (n = 30), the ability of single doses of selegiline to modify naloxone-precipitated withdrawal was determined. After pretreatment with noncontingent morphine to establish opiate dependence, rats acquired self-administration of intravenous morphine. Daily intravenous treatment with saline or 2.0mg kg(-1) doses of selegiline was then initiated and continued over 14 days during extinction, reinstatement, and reacquisition of morphine self-administration. To reduce the potential for psychostimulant effects, selegiline was administered approximately 1h following self-administration, extinction, or reinstatement sessions. In some animals (n = 23), effects of saline or selegiline administration on locomotor activity were determined following extinction sessions. Daily selegiline treatment decreased the number of ratios completed and increased response latency during extinction, without modifying these measures during reinstatement or reacquisition of morphine self-administration. Chronic selegiline treatment increased locomotor activity recorded between 4 and 7h after selegiline administration on day 7 of extinction, but otherwise did not alter locomotor activity. Pretreatment with single, 2.0mg kg(-1) doses of selegiline did not modify naloxone-precipitated withdrawal. In conclusion, pretreatment with selegiline produced only a small decrease in responding during extinction of morphine self-administration and did not modify cue-induced reinstatement of morphine-seeking behavior, reacquisition or morphine reinforcement, or precipitated withdrawal.
司来吉兰是一种不可逆的单胺氧化酶(MAO)抑制剂,具有精神兴奋和神经保护作用,可防止阿片类药物戒断后多巴胺外流减少。本研究评估了司来吉兰治疗对Wistar大鼠(n = 26)觅吗啡行为和吗啡强化作用的影响。在另外的动物(n = 30)中,确定了单剂量司来吉兰改变纳洛酮诱发戒断反应的能力。在用非条件性吗啡预处理以建立阿片类药物依赖后,大鼠学会了静脉注射吗啡的自我给药。然后开始每天静脉注射生理盐水或2.0mg kg(-1)剂量的司来吉兰,并在吗啡自我给药的消退、恢复和重新获得过程中持续14天。为了降低精神兴奋作用的可能性,司来吉兰在自我给药、消退或恢复实验后约1小时给药。在一些动物(n = 23)中,在消退实验后确定了生理盐水或司来吉兰给药对运动活动的影响。每天给予司来吉兰治疗可减少消退期间完成的比率数量并增加反应潜伏期,而在吗啡自我给药的恢复或重新获得过程中未改变这些指标。慢性司来吉兰治疗增加了消退第7天司来吉兰给药后4至7小时记录的运动活动,但在其他方面未改变运动活动。用单剂量2.0mg kg(-1)的司来吉兰预处理未改变纳洛酮诱发的戒断反应。总之,司来吉兰预处理仅使吗啡自我给药消退期间的反应略有减少,并未改变线索诱导的觅吗啡行为恢复、重新获得或吗啡强化作用,或诱发的戒断反应。